Wang XJ, Wang CY, Xi YF, Bu P, Wang P. Ovarian mucinous tumor with mural nodules of anaplastic carcinoma: Three case reports. World J Clin Cases 2022; 10(21): 7459-7466 [PMID: 36158006 DOI: 10.12998/wjcc.v10.i21.7459]
Corresponding Author of This Article
Pei Wang, MD, Doctor, Department of Gynecology, Shanxi Cancer Hospital and Institute, No. 3 Zhigongxin Village, Xinghualing District, Taiyuan 030013, Shanxi Province, China. wangpei674325@sina.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 26, 2022; 10(21): 7459-7466 Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7459
Ovarian mucinous tumor with mural nodules of anaplastic carcinoma: Three case reports
Xiao-Juan Wang, Chun-Yan Wang, Yan-Feng Xi, Peng Bu, Pei Wang
Xiao-Juan Wang, Yan-Feng Xi, Peng Bu, Department of Pathology, Shanxi Cancer Hospital and Institute, Taiyuan 030013, Shanxi Province, China
Chun-Yan Wang, Department of Molecular Biology, Department of Blood Transfusion, Shanxi Cancer Hospital and Institute, Taiyuan 030013, Shanxi Province, China
Pei Wang, Department of Gynecology, Shanxi Cancer Hospital and Institute, Taiyuan 030013, Shanxi Province, China
Author contributions: Wang XJ and Bu P performed histological and immunohistochemical evaluation; Wang XJ and Xi YF were involved in the literature review and drafted the manuscript; Wang CY was involved in collecting clinical data; Wang P participated in the correspondence and reviewing and editing of the drafted manuscript as per journal policy and its submission; All authors read and approved the final manuscript.
Supported bythe Medical Key Science Project of Shanxi Province, No. 2020XM52; and the Scientific and Technological Activities for Overseas Students in Shanxi Province, No. 20200042.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and all accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Pei Wang, MD, Doctor, Department of Gynecology, Shanxi Cancer Hospital and Institute, No. 3 Zhigongxin Village, Xinghualing District, Taiyuan 030013, Shanxi Province, China. wangpei674325@sina.com
Received: November 3, 2021 Peer-review started: November 3, 2021 First decision: December 27, 2021 Revised: January 8, 2022 Accepted: June 4, 2022 Article in press: June 4, 2022 Published online: July 26, 2022 Processing time: 250 Days and 1.4 Hours
Core Tip
Core Tip: Anaplastic carcinoma mural nodules in ovarian mucinous tumors are rare. The pathomorphological features, molecular detection results, clinical treatment and prognosis of anaplastic carcinoma mural nodules were described in three cases. After limited molecular detection, it is inferred that the mural nodules of anaplastic carcinoma may arise from (1) dedifferentiation of mucinous tumors or (2) a tumor unrelated to mucinous tumors and the KRAS signal pathway may be involved in the formation of this tumor and is unrelated to mucinous tumors. The KRAS signal pathway may be involved in the formation of mural nodules of anaplastic carcinoma. The mural nodules of anaplastic carcinoma may promote the progression of borderline mucinous ovarian tumors.
